Walgreen (WAG) Comps Make Strong Gains in January; May Signal Rebound
Tweet Send to a FriendGet Alerts WAG Hot Sheet
Price: $50.53 +0.26%
Rating Summary:
14 Buy, 7 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Rating Summary:
14 Buy, 7 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Trade WAG Now!
Walgreen (NYSE: WAG) is trading strong following January retail sales results, which were issued ahead of the bell Tuesday morning. Comps rose 3.7 percent for the month, while overall sales rose 6.3 percent.
Goldman Sachs noted that January comps beat its above-the-Street estimate calling for a 3.1 percent gain. Front-end comps fell 0.4 percent, besting Goldman's expectations of a 2 percent drop. The firm believes the better result was due in part to over-the-counter cough/cold/flu remedies.
Pharmacy comps rose 6.2 percent, versus Goldman's expectation of a 6.3 percent gain. Comparable-store prescription count, excluding the impact of flu and calendar shifts, rose 7.3 percent, versus the firms 7.0 percent outlook. The result was an "impressive acceleration" from a 1.9 percent drop in December.
Flu and flu shots are estimated to have added 4.3 points to prescriptions comps and 2.6 points to pharmacy dollars.
Overall, Goldman sees the numbers bolstering perceptions of Walgreen, particularly since getting hit in 2011 - 12. Into Walgreen's analyst meeting in February, Goldman sees the company reinforcing synergies in the Alliance-Boots acquisition, as well as the potential enhancement to Walgreen from Alliance-Boots skill sets and incremental governance.
Shares of Walgreen are up over 3 percent Tuesday. Goldman rates Walgreen at Buy with a $44 price target.
For an analyst ratings summary and ratings history on Walgreen click here. For more ratings news on Walgreen click here.
Shares of Walgreen closed at $40.01 yesterday, with a 52 week range of $28.53-$40.47.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Goldman Sachs noted that January comps beat its above-the-Street estimate calling for a 3.1 percent gain. Front-end comps fell 0.4 percent, besting Goldman's expectations of a 2 percent drop. The firm believes the better result was due in part to over-the-counter cough/cold/flu remedies.
Pharmacy comps rose 6.2 percent, versus Goldman's expectation of a 6.3 percent gain. Comparable-store prescription count, excluding the impact of flu and calendar shifts, rose 7.3 percent, versus the firms 7.0 percent outlook. The result was an "impressive acceleration" from a 1.9 percent drop in December.
Flu and flu shots are estimated to have added 4.3 points to prescriptions comps and 2.6 points to pharmacy dollars.
Overall, Goldman sees the numbers bolstering perceptions of Walgreen, particularly since getting hit in 2011 - 12. Into Walgreen's analyst meeting in February, Goldman sees the company reinforcing synergies in the Alliance-Boots acquisition, as well as the potential enhancement to Walgreen from Alliance-Boots skill sets and incremental governance.
Shares of Walgreen are up over 3 percent Tuesday. Goldman rates Walgreen at Buy with a $44 price target.
For an analyst ratings summary and ratings history on Walgreen click here. For more ratings news on Walgreen click here.
Shares of Walgreen closed at $40.01 yesterday, with a 52 week range of $28.53-$40.47.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Walgreens Mobilizes for Oklahoma Tornado Victims
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Dollar Tree (DLTR) Beats But Looks Stretched - Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Retail SalesRelated Entities
Goldman Sachs
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
